(4-甲基-2-苯基-1,3-噻唑-5-基)甲醇 | 61291-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (4-甲基-2-苯基-1,3-噻唑-5-基)甲醇
• 英文名称: (4-methyl-2-phenylthiazole-5-yl)methanol
• 英文别名: 4-methyl-2-phenyl-5-thiazolemethanol；(4-Methyl-2-phenyl-1,3-thiazol-5-yl)methanol
• CAS: 61291-91-6
• 化学式: C₁₁H₁₁NOS
• mdl: MFCD01928782
• 分子量: 205.28
• InChiKey: JSIPFWSPCWZJIU-UHFFFAOYSA-N

物化性质

• 熔点：
  99 °C
• 沸点：
  386.3±34.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090
• 安全说明：
  S24/25

SDS

Name:	(4-Methyl-2-phenyl-1 3-thiazol-5-yl)methanol Material Safety Data Sheet
Synonym:	None Known
CAS:	61291-91-6

Section 1 - Chemical Product MSDS Name:(4-Methyl-2-phenyl-1 3-thiazol-5-yl)methanol Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
61291-91-6	(4-Methyl-2-phenyl-1,3-thiazol-5-yl)me	100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 61291-91-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 99 - 102 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11NOS
Molecular Weight: 205.27

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 61291-91-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4-Methyl-2-phenyl-1,3-thiazol-5-yl)methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 61291-91-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 61291-91-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 61291-91-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4-甲基-2-苯基-1,3-噻唑-5-基)甲醇 在 二甲基亚砜 、 2-碘酰基苯甲酸 作用下， 反应 0.5h， 生成 4-甲基-2-苯基-1,3-噻唑-5-甲醛
  参考文献：
  名称：

  新型3-（4-（2-（2-取代噻唑-4-基）苯基）-2-（4-甲基-2-取代噻唑-5-基）噻唑烷-4-酮衍生物的合成及抗菌活性

  摘要：

  在本研究中，一系列新的3-（4-（2-取代噻唑-4-基）苯基）-2-（4-甲基-2-取代噻唑-5基）噻唑烷-4-酮衍生物是合成方法是将2-取代4-甲基噻唑5-甲醛与4-（2-取代噻唑4-基）苯甲胺缩合，然后与巯基乙酸在甲苯中进行环缩合。所有新合成的化合物均通过光谱（IR，1 H NMR，13 C NMR和Mass）方法进行了表征。筛选标题化合物的定量抗菌活性（最小抑制浓度）。所有化合物7a，7b，7c，7d，7e，7f，7g，7h和8a，8b，8c，8d，8e，8f，8g，8h显示中度至良好的抗菌活性，而化合物（7a，7b，7c，7d，7e，7f，7g，7h）也显示中度抗真菌活性。

  DOI：

  10.1002/jhet.1789
• 作为产物：
  描述：

  硫代苯甲酰胺 在 lithium aluminium tetrahydride 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 8.0h， 生成 (4-甲基-2-苯基-1,3-噻唑-5-基)甲醇
  参考文献：
  名称：

  微波辅助无溶剂合成一些新型噻唑取代缩氨基硫脲类似物：抗菌和抗癌研究

  摘要：

  对抗生素耐药性的增加迫使研究人员设计针对多重耐药病原微生物的新型活性化合物。通过氨基硫脲与2-芳基-4-甲酰基噻唑、2-芳基-5-甲酰基-4-甲基噻唑和/或5-乙酰基-2-芳基-4-甲基噻唑化合物反应合成了一系列缩氨基硫脲衍生物。评估了这些基于缩氨基硫脲的噻唑加合物对结核病 H37Ra 和牛 BCG 分枝杆菌的抑制活性。他们针对两种癌细胞系评估了它们的细胞毒性：结肠癌（HCT-116）和宫颈癌（HeLa）。值得注意的是，即使在最高浓度下，这些缩氨基硫脲对这些细胞系也表现出最小的细胞毒性作用。此外，所制备的缩氨基硫脲衍生物对枯草芽孢杆菌和金黄色葡萄球菌（革兰氏阳性细菌病原体）以及大肠杆菌和荧光假单胞菌（革兰氏阴性细菌病原体）具有显着的抗菌功效。虽然大多数制备的缩氨基硫脲衍生物对白色念珠菌（一种真菌菌株）表现出中等活性，但其性能值得注意。缩氨基硫脲基噻唑加合物也采用无溶剂方法在微波辐射下成功合

  DOI：

  10.1002/bio.4587

文献信息

• Design, synthesis and Structure–activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Qianqian Qiu、Xue Xu、Xuekun Wang、Lei Jiao、Xin Su、Miaobo Pan、Wenlong Huang、Hai Qian

  DOI：10.1016/j.ejmech.2016.02.040

  日期：2016.5

  The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。
• PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  申请人：Bristol-Myers Squibb Company

  公开号：US20150232463A1

  公开（公告）日：2015-08-20

  The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及公式I、II、III和IV的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。
• Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides
  作者：Bohdan Waszkowycz、Kate M. Smith、Alison E. McGonagle、Allan M. Jordan、Ben Acton、Emma E. Fairweather、Louise A. Griffiths、Niall M. Hamilton、Nicola S. Hamilton、James R. Hitchin、Colin P. Hutton、Dominic I. James、Clifford D. Jones、Stuart Jones、Daniel P. Mould、Helen F. Small、Alexandra I. J. Stowell、Julie A. Tucker、Ian D. Waddell、Donald J. Ogilvie

  DOI：10.1021/acs.jmedchem.8b01407

  日期：2018.12.13

  DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential

  DNA损伤修复酶是开发用于多种癌症和其他潜在疾病的新型治疗剂的有希望的目标。聚（ADP-核糖）糖水解酶（PARG）在调节DNA修复机制中起着关键作用。然而，由于缺乏用于细胞和体内模型的有效药物样抑制剂，限制了其作为新型治疗靶标的潜力的研究。通过将人类PARG的晶体结构与弱活性和具有细胞毒性的蒽醌8a配合使用，已通过基于结构的虚拟筛选和库设计方法鉴定了新型喹唑啉二酮磺酰胺类PARG抑制剂。1-氧杂-3-基甲基衍生物33d和35d选择用于体内的初步研究。X射线晶体结构有助于合理化所观察到的这些新型抑制剂的构效关系。
• Synthesis and Antimicrobial Activities of Novel Series of 3-(4-(2-substituted thiazol-4-yl)phenyl)-2-(4-methyl-2-substituted thiazol-5-yl)thiazolidin-4-one Derivatives
  作者：Shivaji H. Shelke、Pravin C. Mhaske、Sachin Narkhade、Vivek D. Bobade

  DOI：10.1002/jhet.1789

  日期：2014.7

  In the present investigation, a novel series of 3‐(4‐(2‐substituted thiazol‐4‐yl)phenyl)‐2‐(4‐methyl‐2‐substituted thiazol‐5‐yl)thiazolidin‐4‐one derivatives were synthesized by condensation of 2‐substituted‐4‐methylthiazole‐5‐carbaldehyde with 4‐(2‐substituted thiazol‐4‐yl)benzenamine followed by cyclo‐condensation with thioglycolic acid in toluene. All the newly synthesized compounds were characterized

  在本研究中，一系列新的3-（4-（2-取代噻唑-4-基）苯基）-2-（4-甲基-2-取代噻唑-5基）噻唑烷-4-酮衍生物是合成方法是将2-取代4-甲基噻唑5-甲醛与4-（2-取代噻唑4-基）苯甲胺缩合，然后与巯基乙酸在甲苯中进行环缩合。所有新合成的化合物均通过光谱（IR，1 H NMR，13 C NMR和Mass）方法进行了表征。筛选标题化合物的定量抗菌活性（最小抑制浓度）。所有化合物7a，7b，7c，7d，7e，7f，7g，7h和8a，8b，8c，8d，8e，8f，8g，8h显示中度至良好的抗菌活性，而化合物（7a，7b，7c，7d，7e，7f，7g，7h）也显示中度抗真菌活性。
• [EN] NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS<br/>[FR] NOUVEAUX COMPOSES 2-ARYLTHIAZOLE UTILISES COMME AGONISTES DES RECEPTEURS PPARALPHA ET PPARGAMMA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004020420A1

  公开（公告）日：2004-03-11

  The present invention relates to compounds of formula (I) wherein Rl to R10, X, Y and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

  本发明涉及式(I)的化合物，其中R1至R10、X、Y和n如描述和权利要求中所定义，并且其药学上可接受的盐和酯。这些化合物对于治疗疾病如糖尿病是有用的。